Music |
Video |
Movies |
Chart |
Show |
First-line Therapy for HR-positive, HER2-negative, mBC (AJMCtv) View |
ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne (European Society for Medical Oncology (ESMO)) View |
CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer (VJOncology) View |
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC (ecancer) View |
Hormone Receptor Positive, HER2- Breast Cancer Clinical Trial (Big Ten Cancer Research Consortium) View |
Camizestrant may be superior to fulvestrant in patients with HR-positive, HER2-negative BC (ecancer) View |
Foundation Frontiers: Advanced Breast Cancer - Updates to HR+/HER2- Treatment Landscape (Foundation Medicine) View |
Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive ... (ecancer) View |
Optimisation of Treatment Selection u0026 Sequencing Decisions in ER+/HER2- Breast Cancer (COR2ED The Heart of Medical Education) View |
Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients (ecancer) View |